Skip to main content
. 2024 Mar 3;30(3):e14654. doi: 10.1111/cns.14654

FIGURE 6.

FIGURE 6

SPAK inhibitor ZT‐1a inhibits expressions of tNKCC1, pNKCC1, and GFAP, and prevents MBP loss in the corpus callosum (CC) after BCAS. (A, B) ZT‐1a treatment prevents BCAS‐induced increased expression of GFAP and loss of MBP in mouse brain 5 weeks after BCAS. Data are mean ± SEM; one‐way ANOVA, Tukey's post hoc test; n = 3–4; *p < 0.05, **p < 0.01. (C–F) ZT‐1a‐treated mice exhibit decreased expressions of NKCC1 and GFAP proteins in GFAP+ astrocytes in CC compared to Veh‐treated mice at 5 weeks after BCAS. Data are mean ± SEM; one‐way ANOVA, Tukey's post hoc test; n = 3–4; **p < 0.01.